ACVR2B

Activin receptor type-2B · Q13705 · ACVR2B on Sugi Atlas →

3,123 patent compounds predicted against ACVR2B, 2,636 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Saracatinib (SCHEMBL41547)	1.00	1/20
Vx-702 (SCHEMBL185712)	1.00	1/20
SCHEMBL456393	1.00	1/20
Azd-7762 (SCHEMBL1127614)	1.00	1/20
Azd-7762 (SCHEMBL1564574)	1.00	1/20
Gsk-1070916 (SCHEMBL4305006)	1.00	1/20
Saracatinib (SCHEMBL4255230)	0.99	1/20
Hydrochloric Acid (SCHEMBL2059683)	0.98	1/20
SCHEMBL3203253	0.93	1/20
Azd-7762 (SCHEMBL1127337)	0.92	1/20
SCHEMBL4272189	0.89	1/20
SCHEMBL3202847	0.89	1/20
Saracatinib (SCHEMBL4260310)	0.89	1/20
Saracatinib (SCHEMBL4260314)	0.89	1/20
SCHEMBL3206728	0.88	1/20
SCHEMBL4316846	0.87	1/20
SCHEMBL4305024	0.86	1/20
SCHEMBL1564888	0.85	1/20
SCHEMBL4310001	0.85	1/20
SCHEMBL4308835	0.85	1/20

Clinical trials — most relevant to ACVR2B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)	PHASE4	COMPLETED
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies	PHASE2/PHASE3	NOT_YET_RECRUITING
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	PHASE2	COMPLETED
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor	PHASE1/PHASE2	COMPLETED
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer	PHASE2	COMPLETED
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)	PHASE2	COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors	PHASE1	COMPLETED
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy	PHASE1	COMPLETED
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults	PHASE1	NOT_YET_RECRUITING
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension	nan	COMPLETED
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension	nan	UNKNOWN
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies	nan	UNKNOWN
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers	nan	COMPLETED
Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.	nan	RECRUITING
StratosPHere (Non-interventional Study)	nan	COMPLETED
Luspatercept in Metastatic AGCT of the Ovary	nan	COMPLETED
Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia	nan	RECRUITING
National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension	nan	UNKNOWN
BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension	nan	COMPLETED
Urinary Activin A as Apredictive Marker for Assessement of Acute Kidney Injury Severity in Patient Admitted at Assuit University Hospital	nan	NOT_YET_RECRUITING
Influence of Sarcopenia on the Course of the Diseases	nan	RECRUITING
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals	nan	RECRUITING
The PAH Platform for Deep Phenotyping in Korean Subjects	nan	UNKNOWN
Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension	nan	COMPLETED
Genetic and Environmental Characteristics of Primary Pulmonary Hypertension	nan	COMPLETED
European Registry of Acutely Decompensated Pulmonary Arterial Hypertension	nan	NOT_YET_RECRUITING
Circulating Activin-A and FSTL3 in Precapillary Pulmonary Hypertension	nan	ACTIVE_NOT_RECRUITING
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH	nan	WITHDRAWN
Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ACVR2B binder may also engage these)

Protein	Name	Similarity
P27040	—	1.000	P27040 →
Q66T47	—	1.000	Q66T47 →
Q95126	—	1.000	Q95126 →
P38445	—	1.000	P38445 →
ACVR2A	Activin receptor type-2A	1.000	landscape →
P27041	—	0.997	P27041 →
Q28560	—	0.996	Q28560 →
Q90670	—	0.995	Q90670 →
P27039	—	0.990	P27039 →
Q28043	—	0.989	Q28043 →
P38444	—	0.989	P38444 →
P27038	—	0.984	P27038 →
Q90669	—	0.981	Q90669 →
P35739	—	0.976	P35739 →
Q9Z138	—	0.975	Q9Z138 →
Q3UFB7	—	0.974	Q3UFB7 →
Q5RAN0	—	0.974	Q5RAN0 →
MAP4K2	Mitogen-activated protein kinase kinase kinase kinase 2	0.974	landscape →
P80203	—	0.974	P80203 →
Q61288	—	0.972	Q61288 →
ARAF	Serine/threonine-protein kinase A-Raf	0.970	landscape →
ACVRL1	Activin receptor type-1-like	0.970	landscape →
P53669	—	0.969	P53669 →
Q01974	—	0.968	Q01974 →
AXL	Tyrosine-protein kinase receptor UFO	0.968	landscape →
Q05438	—	0.968	Q05438 →
Q4V8A9	—	0.968	Q4V8A9 →
P38438	—	0.967	P38438 →
NPR1	Atrial natriuretic peptide receptor 1	0.966	landscape →
Q61161	—	0.966	Q61161 →